Pharmacological compounds targeting the histone acetylation/methylation machinery such as HDAC or HMT (G9a) inhibitors, which have been shown to possibly enhance fear-extinction processes or decrease anxiety-like behavior, respectively, in animal models, carry great promise also regarding the exposure-based and thus extinction-related treatment of human fear-, anxiety- and stress-related disorders. The gene discussed is EHMT2; the disease is Anxiety.